Nelly Khidekel

US Patent:

7842517, Nov 30, 2010

Filed:

Jun 15, 2007

Appl. No.:

11/763834

Inventors:

Nelly Khidekel - Pasadena CA, US
Sabine Arndt - Dortmund, DE

Assignee:

California Institute of Technology - Pasadena CA

International Classification:

G01N 33/532
C07H 19/10
C12Q 1/48

US Classification:

436544, 435 15, 536 268

Abstract:

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

US Patent:

8383425, Feb 26, 2013

Filed:

Oct 21, 2010

Appl. No.:

12/909402

Inventors:

Linda Hsieh-Wilson - San Marino CA, US
Nelly Khidekel - Pasadena CA, US
Sabine Arndt - Dortmund, DE

Assignee:

California Institute of Technology - Pasadena CA

International Classification:

G01N 33/532
G01N 33/533
G01N 33/53
C12Q 1/54
C12Q 1/48

US Classification:

436544, 436546, 435 75, 435 14, 435 15

Abstract:

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

US Patent:

20050130235, Jun 16, 2005

Filed:

Nov 17, 2004

Appl. No.:

10/990767

Inventors:

Linda Hsieh-Wilson - San Marino CA, US
Nelly Khidekel - Pasadena CA, US
Sabine Arndt - Dortmund, DE

International Classification:

C12Q001/68
G01N033/53
G01N033/20

US Classification:

435007500, 530395000, 436084000

Abstract:

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

US Patent:

20130183712, Jul 18, 2013

Filed:

Feb 22, 2013

Appl. No.:

13/773966

Inventors:

California Institute of Technology - Pasadena CA, US
Nelly Khidekel - Pasadena CA, US
Sabine Arndt - Dortmund, DE

Assignee:

CALIFORNIA INSTITUTE OF TECHNOLOGY - Pasadena CA

International Classification:

G01N 33/68
C07K 19/00
C12N 9/96
C07H 19/10

US Classification:

435 681, 536 2623, 530402, 530395, 435188, 530408, 530410, 530409

Abstract:

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an enginered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

US Patent:

20150344932, Dec 3, 2015

Filed:

Dec 23, 2014

Appl. No.:

14/581603

Inventors:

- PASADENA CA, US
NELLY KHIDEKEL - PASADENA CA, US
SABINE ARNDT - DORTMUND, DE

Assignee:

CALIFORNIA INSTITUTE OF TECHNOLOGY - PASADENA CA

International Classification:

C12Q 1/48
G01N 33/68

Abstract:

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an enginered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.